Owkin is a French-American startup that deploys AI and Federated Learning for medical research.
The company deploys AI and federated learning for medical research and aims to empower researchers in hospitals, universities, and pharmaceutical companies to understand why drug efficacy varies from patient to patient, enhance the drug development process, and identify the best drug for the right patient to improve treatment outcomes. It is backed by investors such as F-Prime Capital & Eight Roads Ventures, GV, Otium Ventures, Cathay Innovation, and NJF Capital as well as a scientific board.
It was co-founded in 2016 by Thomas Clozel, a hematologist oncologist and researcher, and Gilles Wainrib, a computer science teacher-researcher in New York, New York.
B2B
51 to 100
N/A
US $74.1M
Scaling Up
2016
Pharmaceuticals and Medical Products
Managed Health Care
Health Care Facilities & Hospitals
Biotechnology
N/A
Increase Productivity
Analytics
Service
Yes
Active
Machine Learning
Machine Perception
Natural Language Processing
Knowledge Representation and Reasoning
Software
N/A
Nov 2020
- Owkin Announces a New Collaboration to Identify High Immunogenic Epitopes and Candidates for COVID-19 and Coronaviruses Future Vaccines
Oct 2020
- Owkin Wins 2020 MICCAI Distributive and Federated Learning Workshop?s Best Paper Award for its Siloed Federated Learning for Multi-Centric Histopathology Datasets Paper
May 2020
- Owkin Launches the Collaborative COVID-19 Open AI Consortium (COAI)
Biostatistician/Clinical Data Scientist
Paris, Paris
Machine Learning Scientist - Medical Imaging - Intern
Paris, Paris
Machine Learning Engineer
Paris, Paris
Quality Assurance Intern
Paris, Paris
Stage/Alternance Achats
Paris, Paris
AI/ML Professionals
1
1
$180M
Company was founded 2016 and it took almost 5 years (Nov 2021) to raise first external round
Investors
Interested in researching Owkin?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Owkin
